• Exozymes posted a net loss of USD 2.37 million for the three months ended March 31, 2026, widening 27.7% from a year earlier.
• Operating loss widened 22.4% to USD 2.39 million on total operating costs that rose 22.4% to USD 2.39 million.
• Research and development costs nearly doubled to USD 1.12 million, while general and administrative costs fell 8% to USD 1.27 million.
• Cash and cash equivalents dropped 52.5% to USD 1.44 million as operating activities used USD 1.52 million in cash; working capital totaled about USD 507,586.
• Company said existing working capital is not sufficient to fund operations for a full 12-month period and highlighted an S-3 shelf registration for up to USD 50 million, with a preliminary prospectus supplement filed in April for a proposed firm-commitment common-stock offering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023035), on May 14, 2026, and is solely responsible for the information contained therein.